Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[For biliopancreatic malignancy, following CEA as more historical and basic TM of gastrointestinal diseases, the mainstay marker is CA 19-9 as monosialo-ganglioside/glycolipid and sialyl derivative of lacto-N-fucopentaose II (sialyl-Lewis(a), hapten of human Lewis(a) bloodgroup determinant).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[For biliopancreatic malignancy, following CEA as more historical and basic TM of gastrointestinal diseases, the mainstay marker is CA 19-9 as monosialo-ganglioside/glycolipid and sialyl derivative of lacto-N-fucopentaose II (sialyl-Lewis(a), hapten of human Lewis(a) bloodgroup determinant).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[For biliopancreatic malignancy, following CEA as more historical and basic TM of gastrointestinal diseases, the mainstay marker is CA 19-9 as monosialo-ganglioside/glycolipid and sialyl derivative of lacto-N-fucopentaose II (sialyl-Lewis(a), hapten of human Lewis(a) bloodgroup determinant).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[For biliopancreatic malignancy, following CEA as more historical and basic TM of gastrointestinal diseases, the mainstay marker is CA 19-9 as monosialo-ganglioside/glycolipid and sialyl derivative of lacto-N-fucopentaose II (sialyl-Lewis(a), hapten of human Lewis(a) bloodgroup determinant).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP386013.RA47wkipte80PRCz3Z1dl5eDhHoY5-vGJSKqVXcOguYxw130_assertion description "[For biliopancreatic malignancy, following CEA as more historical and basic TM of gastrointestinal diseases, the mainstay marker is CA 19-9 as monosialo-ganglioside/glycolipid and sialyl derivative of lacto-N-fucopentaose II (sialyl-Lewis(a), hapten of human Lewis(a) bloodgroup determinant).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP386013.RA47wkipte80PRCz3Z1dl5eDhHoY5-vGJSKqVXcOguYxw130_provenance.
• NP311961.RAfBMM_OB0RD2JxX2BYBTZ1tqnC7BMpwF21ObvLzxXIbI130_assertion description "[For biliopancreatic malignancy, following CEA as more historical and basic TM of gastrointestinal diseases, the mainstay marker is CA 19-9 as monosialo-ganglioside/glycolipid and sialyl derivative of lacto-N-fucopentaose II (sialyl-Lewis(a), hapten of human Lewis(a) bloodgroup determinant).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP311961.RAfBMM_OB0RD2JxX2BYBTZ1tqnC7BMpwF21ObvLzxXIbI130_provenance.
• NP312246.RAXFoBzQhe0lO4142FzFcPUeWjx6d2ByUDwoaX2HwTEeQ130_assertion description "[For biliopancreatic malignancy, following CEA as more historical and basic TM of gastrointestinal diseases, the mainstay marker is CA 19-9 as monosialo-ganglioside/glycolipid and sialyl derivative of lacto-N-fucopentaose II (sialyl-Lewis(a), hapten of human Lewis(a) bloodgroup determinant).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP312246.RAXFoBzQhe0lO4142FzFcPUeWjx6d2ByUDwoaX2HwTEeQ130_provenance.
• assertion description "[For biliopancreatic malignancy, following CEA as more historical and basic TM of gastrointestinal diseases, the mainstay marker is CA 19-9 as monosialo-ganglioside/glycolipid and sialyl derivative of lacto-N-fucopentaose II (sialyl-Lewis(a), hapten of human Lewis(a) bloodgroup determinant).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP309124.RAhduUFn3x-9ZqsCKjyNYp2B_q47GGqSQug0LQYK-Xc1Q130_assertion description "[For biliopancreatic malignancy, following CEA as more historical and basic TM of gastrointestinal diseases, the mainstay marker is CA 19-9 as monosialo-ganglioside/glycolipid and sialyl derivative of lacto-N-fucopentaose II (sialyl-Lewis(a), hapten of human Lewis(a) bloodgroup determinant).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP309124.RAhduUFn3x-9ZqsCKjyNYp2B_q47GGqSQug0LQYK-Xc1Q130_provenance.
• NP862770.RAKhdI9IO88gtDwJqTh4DcGzZbUWYP9rNKk2uCP7Teo4Y130_assertion description "[For biliopancreatic malignancy, following CEA as more historical and basic TM of gastrointestinal diseases, the mainstay marker is CA 19-9 as monosialo-ganglioside/glycolipid and sialyl derivative of lacto-N-fucopentaose II (sialyl-Lewis(a), hapten of human Lewis(a) bloodgroup determinant).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP862770.RAKhdI9IO88gtDwJqTh4DcGzZbUWYP9rNKk2uCP7Teo4Y130_provenance.
• NP899648.RALtMUJ9oq1EFiWTDMs5KnWC9zNVP3mjHK5z9IJNt3ebo130_assertion description "[For biliopancreatic malignancy, following CEA as more historical and basic TM of gastrointestinal diseases, the mainstay marker is CA 19-9 as monosialo-ganglioside/glycolipid and sialyl derivative of lacto-N-fucopentaose II (sialyl-Lewis(a), hapten of human Lewis(a) bloodgroup determinant).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP899648.RALtMUJ9oq1EFiWTDMs5KnWC9zNVP3mjHK5z9IJNt3ebo130_provenance.
• NP259585.RAYqsopfxTCq0Up_GLEyYTzZdxMbNsMrlB0VFn-EsCwUY130_assertion description "[For biliopancreatic malignancy, following CEA as more historical and basic TM of gastrointestinal diseases, the mainstay marker is CA 19-9 as monosialo-ganglioside/glycolipid and sialyl derivative of lacto-N-fucopentaose II (sialyl-Lewis(a), hapten of human Lewis(a) bloodgroup determinant).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP259585.RAYqsopfxTCq0Up_GLEyYTzZdxMbNsMrlB0VFn-EsCwUY130_provenance.
• NP259587.RAWi_1VbUpAhOqB20WS_Mf-NXSQi1ogSfuzgWlFwZwtQg130_assertion description "[For biliopancreatic malignancy, following CEA as more historical and basic TM of gastrointestinal diseases, the mainstay marker is CA 19-9 as monosialo-ganglioside/glycolipid and sialyl derivative of lacto-N-fucopentaose II (sialyl-Lewis(a), hapten of human Lewis(a) bloodgroup determinant).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP259587.RAWi_1VbUpAhOqB20WS_Mf-NXSQi1ogSfuzgWlFwZwtQg130_provenance.
• NP702298.RAFOwnOvRLPrF6uXeCuM5AUxEnMc1pBObNgAyezA0xJEU130_assertion description "[For biliopancreatic malignancy, following CEA as more historical and basic TM of gastrointestinal diseases, the mainstay marker is CA 19-9 as monosialo-ganglioside/glycolipid and sialyl derivative of lacto-N-fucopentaose II (sialyl-Lewis(a), hapten of human Lewis(a) bloodgroup determinant).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP702298.RAFOwnOvRLPrF6uXeCuM5AUxEnMc1pBObNgAyezA0xJEU130_provenance.
• NP259584.RAng2Tm47V8Md7lsksABRshch2XhHnIKOzUqBJ0fnxlGw130_assertion description "[For biliopancreatic malignancy, following CEA as more historical and basic TM of gastrointestinal diseases, the mainstay marker is CA 19-9 as monosialo-ganglioside/glycolipid and sialyl derivative of lacto-N-fucopentaose II (sialyl-Lewis(a), hapten of human Lewis(a) bloodgroup determinant).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP259584.RAng2Tm47V8Md7lsksABRshch2XhHnIKOzUqBJ0fnxlGw130_provenance.
• NP651207.RA0S0pG_Curx2OPrdGLybOXdGWgA0ahjVfCB4HJQ_j1BA130_assertion description "[For biliopancreatic malignancy, following CEA as more historical and basic TM of gastrointestinal diseases, the mainstay marker is CA 19-9 as monosialo-ganglioside/glycolipid and sialyl derivative of lacto-N-fucopentaose II (sialyl-Lewis(a), hapten of human Lewis(a) bloodgroup determinant).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP651207.RA0S0pG_Curx2OPrdGLybOXdGWgA0ahjVfCB4HJQ_j1BA130_provenance.
• NP259590.RA62lhISiv55bdaspy366UsrsXxD3Ibcv2uQkO90AISN0130_assertion description "[For biliopancreatic malignancy, following CEA as more historical and basic TM of gastrointestinal diseases, the mainstay marker is CA 19-9 as monosialo-ganglioside/glycolipid and sialyl derivative of lacto-N-fucopentaose II (sialyl-Lewis(a), hapten of human Lewis(a) bloodgroup determinant).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP259590.RA62lhISiv55bdaspy366UsrsXxD3Ibcv2uQkO90AISN0130_provenance.